Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Assessing MRD in multiple myeloma

Sham Mailankody • 27 May 2020
ASCO 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma Carfilzomib Dexamethasone Lenalidomide
GEM-CESAR

Sham Mailankody, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses MRD assessment in multiple myeloma (MM). Specifically, Dr Mailankody outlines bone marrow MRD testing, assessed by next-generation flow-cytometry and alternative methods of disease evaluation in serum, such as mass spectrometry. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sham Mailankody

Updates in multiple myeloma
Nizar Bahlis et al. • 14 Apr 2023
2:39
What are the next steps for CAR-T in myeloma?
Sham Mailankody • 8 Dec 2020
5:31
Emerging immunotherapies for myeloma
Sham Mailankody • 8 Dec 2020
4:02
ALLO-715: BCMA allogeneic CAR-T in R/R myeloma
Sham Mailankody • 8 Dec 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals